A recent licensing agreement allows Mylan to commercialise Otsuka Novel Products’ Delamanid (Deltyba) product indicated for pulmonary multidrug-resistant tuberculosis (MDR-TB) in low and middle-income countries such as India and South Africa.

Mylan hopes to expand the commercial rights and registration into other high MDR-TB burden countries where Otsuka has not had commercial presence.

Figure 1 shows the current number of drugs in pipeline development for MDR-TB. It shows there are very few in last-stage clinical trials and there is an opportunity for more companies to invest in this area.

Figure 1: Novel Drugs in Pipeline for Multidrug-Resistant Tuberculosis

Source: GlobalData, Pharma Intelligence Center, Deals Database [Accessed August, 2017]

South Africa and India are considered by the World Health Organization (WHO) as the highest burden countries for MDR-TB. Since 2015, Delamanid was added to the WHO’s essential medicines list and received first regulatory approval from the European Medicines Agency (EMA) in 2014. However, from 2005, Otsuka has contributed $450m in funding, and most recently produced an initiative programme for development of MDR-TB to lead the way for therapies on the market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.